MASS SPECTROMETRY

ACHIEVING PROMINENCE

IN CLINICAL MEDICINE

Dobrin Svinarov

Alexander Hospital

Medical University of Sofia, Bulgaria

SYNOPSIS

- Technological transfer in laboratory medicine
- Principles of modern mass spectrometry
- Expanding role of MS in CLINICAL medicine
  - Chemical pathology: TDM & TOX, Endocrinology, NB screening, microbiology, Clinical chemome as a new diagnostic tool and omics' era diagnostics
  - Anatomical pathology: molecular imaging & I-knife
- The MS role in precision medicine

Technological Transfer in Lab Medicine

Today:

- the era of total laboratory automation
- flood of new technologies:
  - mass spectrometry
  - cell sorting platforms
  - genome assays.

The future:

- microfluidic & in vivo assay platforms
- “omic” research turns into “omic” diagnostics
- big data analysis and patient controlled care

Joseph John Thomson
1865-1940, Cambridge, UK
First mass spectrometer
Nobel Prize in Physics 1906



Francis Wiliam Aston
1877-1945, Cambridge, UK
Mass spectrometry of isotopes
Nobel Prize in Chemistry 1922



Wolfgang Paul
1913-1993, Bonn, Germany
Q and Q Ion trap mass spectrometers
Nobel Prize in Physics 1989



John B Fenn
1917, Richmond, Virginia, USA
Electrospray Ionization of biomolecules
Nobel Prize in Chemistry 2002

Koichi Tanaka
1959, Shimadzu Cooperation,Japan
Matrix Assisted Lazer Desorption Ionisation
Nobel Prize in Chemistry 2002

News & Views the Clinical Chemist

Clinical Chemistry's 2016 Special Issue: Clinical Mass Spectrometry–Achieving Prominence in Laboratory Medicine

Thomas M. Annesley*



Fig. 1. Percent change in the number of publications from 2000 for the topic category "mass spectrometry" (closed circles) versus the percent change in all publications (open circles).

Principle of LC-MS/MS (QQQ)MS





Kobold-U, Scand J Clin & Lab Invest 2012; 72 (Suppl 243):54-59, modified.

Expanding role of mass spectrometry in the medical laboratory

LC-MS/MS (QQQ)

- **TDM** (immunosuppressants, antiretroviral drugs, antidepressants, antipsychotics)
- **Drugs of Abuse & Clinical Toxicology**
- **Endocrinology** (steroid profiles, FT3, FT4, free metanephrines)
- **Newborn screening** (e.g. acylcarnitines, amino acids, steroids)
- **Vitamin D status** (25-OH-D2, 25-OH-D3)
- **Peptidomics** (Angiotensins, Oxytocin, ADH, hepcidine)

MALDI-TOF & ORBITRAP

- **Proteomics** (Research, Biomarker Discovery)
- **Medical Microbiology**

Testosterone определен с IA и LC-MS/MS



Streit et al (unpublished)

High sensitive LC-MS/MS Analysis of Estradiol (E2) in Human Plasma



Post MP Female, E2 1.5 ng/L



Eldery Male, E2 3.6 ng/L





Young Female, E2 152 ng/L



Internal Standard, d_3-E2

File Name	Specified Amount	Calculated Amount	% Diff
CC_00	1.000	0.934	-6.59
CC_01	2.000	2.068	3.42
CC_02	4.000	4.208	5.21
CC_03	10.000	9.857	-1.43
CC_04	20.000	18.193	-9.04
CC_05	40.000	45.714	14.28
CC_06	100.000	98.789	-1.21
CC_07	200.000	192.181	-3.91
CC_08	400.000	391.694	-2.08
CC_09	1000.000	1013.363	1.34

DAS_Antalya_2019

Simultaneous LC-MS/MS Analysis of Cortisol (F)and Testosteron (T) in oral fluid



Calibration Sample01, F 2.8 µg/L



Internal Standard, d4-F





Calibration Sample01, T 6.2 ng/L



Internal Standard, d3-T



DAS_Antalya_2019

Traditional Newborn Screening

- Single Disease
- Single test
- Single Marker
- Single cut-off (N/Abn)



MS/MS Newborn Screening

- Multiple Diseases
- Single test
- Multiple Markers
- Multiple cut-offs

MS/MS Newborn Screening

> 50 ANALYTES > 30 IEM

Time < 2 min

Phenylketonuria
MSUD
Homocystinuria
Tyrosinemia type I
Argininosuccinic acidemia
Citrullinemia type I
Hyperphenylalaninemia
Tyrosinemia type II
Biopterin defects (Bios)
Tyrosinemia type III
Biopterin (Reg)
Argininemia
Hypermethioninemia
Citrullinemia type II

MCAD deficiency
VLCAD deficiency
LCHAD deficiency
TFP deficiency
Carnitine uptake defect
Glutaric acidemia type II

Isovaleric acidemia
Glutaric acidemia type I
Methylglutaconic acidemia
Malonic acidemia
HMG deficiency
3MCC deficiency
BKT deficiency
Multiple carboxylase deficiency
Methylmalonic acidemia (MUT)
Methylmalonic acidemia (Cbl A,B)
Propionic acidemia

Steroid profiling by LC-MS/MS



Steroid profiling by LC-MS/MS



Direct sample introduction via:

- **M**atrix
- **A**ssisted
- **L**azer
- **D**esorption
- **I**onization

Hardware of ToF



Sample
(start point)

Detector

Timing
electronics



MALDI-TOF MS in Medical Microbiology

- Traditional methods require 48 – 72 h and are restricted regarding the number of microorganisms identified
- MALDI-TOF MS detects highly conserved microbial proteins and peptides (mainly ribosomal) and by matching the proteomic fingerprint from the sample to a known database, differentiates thousands of individual pathogens at a species level in a matter of minutes!
  - Major limitation – cannot yet provide atibiotic succeptibilities
  - Future – identification of microbes directly from patient samples



Add Formic Acid and Matrix and Dry





Mayo Clinic
Laboratory Services Report

MICROBIOLOGY

Fungal Culture, Routine FINAL 07/25/2012 14:42 MCR

CANDIDA PARAPSILOSIS Many
Identified by mass spectrometry.

MCR Mayo Clinic Dept.of Laboratory Medicine and Pathology, 200 First Street SW,Rochester,MN 55905 Franklin R.Cockerill, M.D.,Lab Director


1 Sample culture
2 Matrix
3 MALDI-TOF/MS
sample plate


Ion Detector
Ionized Proteins
Mass Analyzer
Laser Beam
Sample Ionization Chamber
Target Plate
Enter TOF Mass Analyzer
Electrostatic Field
Vaporized, Positively Charged Cloud of Sample Proteins and Matrix
Laser Beam
Matrix
Sample
Single Sample Well

Figure Research Topic



Orbitrap™ Mass Spectrometers

Blood-based lipidomic biomarkers for preclinical detection of Alzheimer's disease

- Proof-of-concept study led by H.Federoff, MD, PhD
- By use of MS researchers identified a panel of lipids that could predict the onset of cognitive impairment 2-3 years ahead of clinical manifestation
- In the validation phase they found that a 10-lipid panel predicted the progression from normal to Alzheimer's disease with a sensitivity of 90% and a specificity of 85%, but still with low PPV

Cheema A et all, AACC 2014 Plenary & Nature Medicine, 2014

BUT for LC-MS/MS Problems still Exist!

- High financial investment
- Limited capability for automation
- No random access
- Special expertise required
- LDTs, limited availability of IVD certified kits
- Lack of proficiency testing schemes
- Tedious method validation
- Technical support from manufacturers
- Need for harmonization and standardization
- ……

LC-MS/MS-Kits

BASIC Kit A PLUS **MasterColumn® A**

BASIC Kit A consists of:

- Mobile Phase 1
- Mobile Phase 2
- Precipitation Reagent
- Extraction Buffer
- Dilution Buffer 1
- Dilution Buffer 2
- Rinsing Solution
- Reaction vials

MasterColumn® A: Analytical column: equilibrated, with test chromatogram

PLUS

Single PARAMETER Sets

- Antiarrhythmic Drugs
- Antidepressants 2/ Psychostimulants
- Anti-HIV Drugs
- Benzodiazepines 1
- Mycophenolic Acid
- Neuroleptics 2/ *EXTENDED*
- Tricyclic Antidepressants TCA 2
- Antidepressants 1
- Antiepileptic Drugs
- Antimycotic Drugs
- Benzodiazepines 2
- Neuroleptics 1
- Tricyclic Antidepressants TCA 1

Components of each PARAMETER Set: Multilevel Plasma Calibrator Set (3PLUS1® or 6PLUS1®)
+ *MassCheck®* Plasma Control, Level I and Level II
+ Internal Standard

Waters
THE SCIENCE OF WHAT'S POSSIBLE.™

MassTrak™

RECIPE®

ClinMass® Komplettkit

CHROMSYSTEMS

MassTox® Immunosuppressants in whole blood - ONEMinute Test

MS IMAGING


Cancer Grading
WHO grade II
Tumor Diagnostics
tumor
normal
3D Molecular Images
DESI-MS Imaging
Chemical Fingerprint
Drug Mapping
Analysis of Inks
1982
IYC 2011

I-KNIFE MS IMAGING

Precision Medicine (PM)

- PM also referred as personalized medicine employs investigation of patient's genotype and phenotype to establish individually tailored disease management
  - P4 medicine:
    - Predictive
    - Proactive
    - Participatory
    - Personalized

Genotype versus Phenotype

Phenotype: Variation in Organism as it Changes during Life Span

Catherpillar

Butterfly

The caterpillar and butterfly share exactly the same genome

BUT show a completely different phenotype depending on their stage of life


GENOME: 20 000
TRANSCRIPTOME: 50 000
PROTEOME: 500 000 – 1 000 000
METABOLOME
5 000 0000 – 10 000 000

Precision Medicine with MS?

MS assays provide the actual patient's phenotype with all the environmental, pharmacological and pathological variables.

The ability to perform panel profiling with simultaneous measurement of active compounds, their precursors and metabolites in a single sample enormously amplifies informative value of results with ultimate improvement of patient care.

MAS SSPECTROMETRY – MEDICAL LABORATORY ANALYSER OF THE NEAR FUTURE?

Mass spectrometry analysis of nucleic acids, proteins, low molecular metabolites provides dramatic advantages

High throughput:

Analysis of thousands of components in a drop of blood in several minutes >> hundreds of samples in a single batch

Absolute specificity:

Structural identification of known and unknown components >> direct analysis of PCR products!

Extreme sensitivity:

Quantitative assays in the femtomolar range with use of microvolumes of sample

ATHENS 2017


Introducing the first fully automated
clinical analyzer with integrated
LC-MS/MS technology

CONCLUSION

- Mass spectrometry coupled to adaptive and vigilant bioinformatic pattern-recognition tools will change how disease is detected and monitored
- Thus a transfer to newer biomarkers and disease signatures will open the era of “omics” diagnostics and personal management in clinical medicine
- The result will be a nonlinear advance in our understanding of health, aging, disease, prevention, risk assessment, individualization of therapy, monitoring of relapse... *(Petricoin & Liotta, Clin Chem, 2003)*

Thank you!

Questions?